-
Effects of risk factors on the development and mortality of early- and late-onset dementia: an 11-year longitudinal nationwide population-based cohort study in South Korea Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-25 Min Young Chun, Wonjeong Chae, Sang Won Seo, Hyemin Jang, Jihwan Yun, Duk L. Na, Dongwoo Kang, Jungkuk Lee, Dustin B. Hammers, Liana G. Apostolova, Sung-In Jang, Hee Jin Kim
Early-onset dementia (EOD, onset age < 65) and late-onset dementia (LOD, onset age ≥ 65) exhibit distinct features. Understanding the risk factors for dementia development and mortality in EOD and LOD respectively is crucial for personalized care. While risk factors are known for LOD development and mortality, their impact on EOD remains unclear. We aimed to investigate how hypertension, diabetes mellitus
-
Association of midlife body-weight variability and cycles with earlier dementia onset: a nationwide cohort study Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-25 Yujin Park, Su Hwan Kim, Jiwon Ryu, Hyung-Jin Yoon
Given the rising awareness of health-related lifestyle modifications, the impact of changes in body weight (BW) on cognitive function and dementia generates significant concern. This study aimed to investigate the association between BW changes and dementia in a middle-aged Korean population. A retrospective, population-based longitudinal study was conducted utilizing data from the National Health
-
Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-25 Rongxiang Tang, Erik Buchholz, Anders M. Dale, Robert A. Rissman, Christine Fennema-Notestine, Nathan A. Gillespie, Donald J Hagler, Michael J. Lyons, Michael C. Neale, Matthew S. Panizzon, Olivia K. Puckett, Chandra A. Reynolds, Carol E. Franz, William S. Kremen, Jeremy A. Elman
Plasma neurofilament light chain (NfL) is a promising biomarker of neurodegeneration with potential clinical utility in monitoring the progression of neurodegenerative diseases. However, the cross-sectional associations of plasma NfL with measures of cognition and brain have been inconsistent in community-dwelling populations. We examined these associations in a large community-dwelling sample of early
-
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-23 Sungwoo Kang, Seun Jeon, Young-gun Lee, Byoung Seok Ye
Association of medial temporal lobe (MTL) metabolism with Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) has not been evaluated considering their mixed disease (MD). 131 patients with AD, 133 with DLB, 122 with MD, and 28 normal controls (NCs) underwent neuropsychological tests, assessments for parkinsonism, cognitive fluctuation (CF), and visual hallucinations (VH), and 18F-fluorodeoxyglucose
-
Exploring morphological similarity and randomness in Alzheimer’s disease using adjacent grey matter voxel-based structural analysis Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-23 Ting-Yu Chen, Jun-Ding Zhu, Shih-Jen Tsai, Albert C. Yang
Alzheimer’s disease is characterized by large-scale structural changes in a specific pattern. Recent studies developed morphological similarity networks constructed by brain regions similar in structural features to represent brain structural organization. However, few studies have used local morphological properties to explore inter-regional structural similarity in Alzheimer’s disease. Here, we sourced
-
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-23 Hao Chen, Jin Hu, Shiqi Gui, Qiushuo Li, Jing Wang, Xing Yang, Jingyuan Yang
While evidence supports cognitive reserve (CR) in preserving cognitive function, longitudinal validation of CR proxies, including later-life factors, remains scarce. This study aims to validate CR’s stability over time and its relation to cognitive function in rural Chinese older adults. Within the project on the health status of rural older adults (HSRO), the survey included baseline assessment (2019)
-
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-23 Ingeborg Rasing, Sabine Voigt, Emma A. Koemans, Anna M. de Kort, Thijs W. van Harten, Ellis S. van Etten, Erik W. van Zwet, Erik Stoops, Cindy Francois, Bea H. Kuiperij, Catharina J.M. Klijn, Floris H.B.M. Schreuder, Louise van der Weerd, Matthias J.P. van Osch, Marianne A.A. van Walderveen, Marcel M. Verbeek, Gisela M. Terwindt, Marieke J.H. Wermer
Neurofilament light chain (NFL) is a biomarker for neuroaxonal damage and glial fibrillary acidic protein (GFAP) for reactive astrocytosis. Both processes occur in cerebral amyloid angiopathy (CAA), but studies investigating the potential of NFL and GFAP as markers for CAA are lacking. We aimed to investigate NFL and GFAP as biomarkers for neuroaxonal damage and astrocytosis in CAA. For this cross-sectional
-
Who am I with my Lewy bodies? The insula as a core region of the self-concept networks Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-19 Alice Tisserand, Frédéric Blanc, Mary Mondino, Candice Muller, Hélène Durand, Catherine Demuynck, Paulo Loureiro de Sousa, Alix Ravier, Léa Sanna, Anne Botzung, Nathalie Philippi
Dementia with Lewy bodies (DLB) is characterized by insular atrophy, which occurs at the early stage of the disease. Damage to the insula has been associated with disorders reflecting impairments of the most fundamental components of the self, such as anosognosia, which is a frequently reported symptom in patients with Lewy bodies (LB). The purpose of this study was to investigate modifications of
-
Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS) Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-16 Zhen Liu, Dai Shi, Yue Cai, Anqi Li, Guoyu Lan, Pan Sun, Lin Liu, Yalin Zhu, Jie Yang, Yajing Zhou, Lizhi Guo, Laihong Zhang, Shuqing Deng, Shuda Chen, Xianfeng Yu, Xuhui Chen, Ruiyue Zhao, Qingyong Wang, Pengcheng Ran, Linsen Xu, Liemin Zhou, Kun Sun, Xinlu Wang, Qiyu Peng, Ying Han, Tengfei Guo
The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge of Alzheimer’s disease (AD). However, the characteristics and prevalence of AD in this area are still unclear due to the rarely available community-based neuroimaging AD cohort. Following the standard protocols of the Alzheimer’s Disease Neuroimaging Initiative, the Greater-Bay-Area
-
Prefrontal intra-individual ERP variability and its asymmetry: exploring its biomarker potential in mild cognitive impairment Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-13 Joel Eyamu, Wuon-Shik Kim, Kahye Kim, Kun Ho Lee, Jaeuk U. Kim
The worldwide trend of demographic aging highlights the progress made in healthcare, albeit with health challenges like Alzheimer’s Disease (AD), prevalent in individuals aged 65 and above. Its early detection at the mild cognitive impairment (MCI) stage is crucial. Event-related potentials (ERPs) obtained by averaging EEG segments responded to repeated events are vital for cognitive impairment research
-
Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-13 Xiaoling Wang, Xiaomin Zhang, Jing Liu, Jingjing Zhang, Congcong Liu, Yuting Cui, Qiao Song, Yuli Hou, Yaqi Wang, Qian Zhang, Yingzhen Zhang, Yujian Fan, Jianping Jia, Peichang Wang
Previous studies have demonstrated that early intervention was the best plan to inhibit the progression of Alzheimer’s disease (AD), which relied on the discovery of early diagnostic biomarkers. In this study, synaptic vesicle glycoprotein 2 A (SV2A) was examined to improve the early diagnostic efficiency in AD. In this study, biomarker testing was performed through the single-molecule array (Simoa)
-
Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-12 Zsolt Huszár, Marie Anne Engh, Márk Pavlekovics, Tomoya Sato, Yalea Steenkamp, Bernard Hanseeuw, Tamás Terebessy, Zsolt Molnár, Péter Hegyi, Gábor Csukly
Measurement of beta-amyloid (Aβ) and phosphorylated tau (p-tau) levels offers the potential for early detection of neurocognitive impairment. Still, the probability of developing a clinical syndrome in the presence of these protein changes (A+ and T+) remains unclear. By performing a systematic review and meta-analysis, we investigated the risk of mild cognitive impairment (MCI) or dementia in the
-
Subclinical epileptiform discharges in Alzheimer’s disease are associated with increased hippocampal blood flow Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-12 Christian Sandøe Musaeus, Troels Wesenberg Kjaer, Ulrich Lindberg, Mark B. Vestergaard, Henrik Bo, Wiberg Larsson, Daniel Zvi Press, Birgitte Bo Andersen, Peter Høgh, Preben Kidmose, Martin Christian Hemmsen, Mike Lind Rank, Steen Gregers Hasselbalch, Gunhild Waldemar, Kristian Steen Frederiksen
In epilepsy, the ictal phase leads to cerebral hyperperfusion while hypoperfusion is present in the interictal phases. Patients with Alzheimer’s disease (AD) have an increased prevalence of epileptiform discharges and a study using intracranial electrodes have shown that these are very frequent in the hippocampus. However, it is not known whether there is an association between hippocampal hyperexcitability
-
Biophysical models applied to dementia patients reveal links between geographical origin, gender, disease duration, and loss of neural inhibition Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-11 Sebastian Moguilner, Rubén Herzog, Yonatan Sanz Perl, Vicente Medel, Josefina Cruzat, Carlos Coronel, Morten Kringelbach, Gustavo Deco, Agustín Ibáñez, Enzo Tagliazucchi
The hypothesis of decreased neural inhibition in dementia has been sparsely studied in functional magnetic resonance imaging (fMRI) data across patients with different dementia subtypes, and the role of social and demographic heterogeneities on this hypothesis remains to be addressed. We inferred regional inhibition by fitting a biophysical whole-brain model (dynamic mean field model with realistic
-
Neuroinflammation increases oxygen extraction in a mouse model of Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-10 Chang Liu, Alfredo Cárdenas-Rivera, Shayna Teitelbaum, Austin Birmingham, Mohammed Alfadhel, Mohammad A. Yaseen
Neuroinflammation, impaired metabolism, and hypoperfusion are fundamental pathological hallmarks of early Alzheimer’s disease (AD). Numerous studies have asserted a close association between neuroinflammation and disrupted cerebral energetics. During AD progression and other neurodegenerative disorders, a persistent state of chronic neuroinflammation reportedly exacerbates cytotoxicity and potentiates
-
Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-10 Motonobu Fujishima, Yohei Kawasaki, Toshiharu Mitsuhashi, Hiroshi Matsuda
Individuals on the preclinical Alzheimer's continuum, particularly those with both amyloid and tau positivity (A + T +), display a rapid cognitive decline and elevated disease progression risk. However, limited studies exist on brain atrophy trajectories within this continuum over extended periods. This study involved 367 ADNI participants grouped based on combinations of amyloid and tau statuses determined
-
Equine-assisted services for people living with dementia: a systematic review Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-09 Menka Sebalj, Ali Lakhani, Andrea Grindrod, Rwth Stuckey
Dementia has a significant impact on the social, physical, and psychological wellbeing of people living with dementia, their families and society. Animal-assisted interventions can have positive effects on the health and wellbeing of people living with dementia. Equine-assisted services are animal-assisted non-pharmacological interventions which have improved the health and wellbeing of diverse populations
-
Use of a digital tool to support the diagnostic process in memory clinics–a usability study Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-08 Aniek M. van Gils, Hanneke F. M. Rhodius-Meester, Dédé Handgraaf, Heleen M. A. Hendriksen, Astrid van Strien, Niki Schoonenboom, Annemieke Schipper, Mariska Kleijer, Annemiek Griffioen, Majon Muller, Antti Tolonen, Jyrki Lötjönen, Wiesje M. van der Flier, Leonie N. C. Visser
Both memory clinic professionals and patients see value in digital tools, yet these hardly find their way to clinical practice. We explored the usability of a digital tool to support the diagnostic work-up in daily memory clinic practice. We evaluated four modules that integrate multi-modal patient data (1.cognitive test; cCOG, and 2. MRI quantification; cMRI) into useful diagnostic information for
-
Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-06 Kanishk Kaushik, Anna M. de Kort, Rosemarie van Dort, Reinier G.J. van der Zwet, Bob Siegerink, Sabine Voigt, Erik W. van Zwet, Maaike C. van der Plas, Emma A. Koemans, Ingeborg Rasing, Roy P.C. Kessels, Huub A.M. Middelkoop, Floris H.B.M. Schreuder, Catharina J.M. Klijn, Marcel M. Verbeek, Gisela M. Terwindt, Ellis S. van Etten, Marieke J.H. Wermer
Neuropsychiatric symptoms (NPS) may affect cognition, but their burden in cerebral amyloid angiopathy (CAA), one of the main causes of intracerebral hemorrhage (ICH) and dementia in the elderly, remains unclear. We investigated NPS, with emphasis on apathy and irritability in sporadic (sCAA) and Dutch-type hereditary (D-)CAA. We included patients with sCAA and (pre)symptomatic D-CAA, and controls from
-
Utility of visual rating scales in primary progressive aphasia Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-06 Neus Falgàs, Luca Sacchi, Tiziana Carandini, Nuria Montagut, Giorgio Conte, Fabio Triulzi, Daniela Galimberti, Andrea Arighi, Raquel Sanchez-Valle, Giorgio Giulio Fumagalli
Differential diagnosis among subjects with Primary Progressive Aphasia (PPA) can be challenging. Structural MRI can support the clinical profile. Visual rating scales are a simple and reliable tool to assess brain atrophy in the clinical setting. The aims of the study were to establish to what extent the visual rating scales could be useful in the differential diagnosis of PPA, to compare the clinical
-
Vascular dysfunction in sporadic bvFTD: white matter hyperintensity and peripheral vascular biomarkers Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-05 Min Chu, Deming Jiang, Haitian Nan, Lulu Wen, Li Liu, Miao Qu, Liyong Wu
Vascular dysfunction was recently reported to be involved in the pathophysiological process of neurodegenerative diseases, but its role in sporadic behavioral variant frontotemporal dementia (bvFTD) remains unclear. The aim of this study was to systematically explore vascular dysfunction, including changes in white matter hyperintensities (WMHs) and peripheral vascular markers in bvFTD. Thirty-two
-
Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-05 Douglas M. Lopes, Jack A. Wells, Da Ma, Lauren Wallis, Daniel Park, Sophie K. Llewellyn, Zeshan Ahmed, Mark F. Lythgoe, Ian F. Harrison
The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms
-
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-04 Heather M. Terron, Sagar J. Parikh, Samer O. Abdul-Hay, Tomoko Sahara, Dongcheul Kang, Dennis W. Dickson, Paul Saftig, Frank M. LaFerla, Shelley Lane, Malcolm A. Leissring
Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid-β protein (Aβ) and the microtubule-associated protein, tau, which accumulate pathognomonically in Alzheimer disease (AD), but few studies have examined the role of CatD in the development of Aβ pathology and tauopathy in vivo. CatD knockout (KO) mice were crossed to human amyloid precursor protein (hAPP) transgenic mice, and
-
Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-03 Qingze Zeng, Yanbo Wang, Shuyue Wang, Xiao Luo, Kaicheng Li, Xiaopei Xu, Xiaocao Liu, Luwei Hong, Jixuan Li, Zheyu Li, Xinyi Zhang, Siyan Zhong, Zhirong Liu, Peiyu Huang, Yanxing Chen, Minming Zhang
Neuropsychiatric symptoms (NPS) are prevalent in cognitively impaired individuals including Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI). Whereas several studies have reported the associations between NPS with AD pathologic biomarkers and cerebral small vessel disease (SVD), but it remains unknown whether AD pathology and SVD contribute to different sub-syndromes independently
-
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-03 Jose L. Cantero, Mercedes Atienza, Isabel Sastre, María Jesús Bullido
Mounting data suggests that herpes simplex virus type 1 (HSV-1) is involved in the pathogenesis of AD, possibly instigating amyloid-beta (Aβ) accumulation decades before the onset of clinical symptoms. However, human in vivo evidence linking HSV-1 infection to AD pathology is lacking in normal aging, which may contribute to the elucidation of the role of HSV-1 infection as a potential AD risk factor
-
White matter hyperintensity patterns: associations with comorbidities, amyloid, and cognition Alz. Res. Therapy (IF 8.823) Pub Date : 2024-04-01 Dario Bachmann, Bettina von Rickenbach, Andreas Buchmann, Martin Hüllner, Isabelle Zuber, Sandro Studer, Antje Saake, Katrin Rauen, Esmeralda Gruber, Roger M. Nitsch, Christoph Hock, Valerie Treyer, Anton Gietl
White matter hyperintensities (WMHs) are often measured globally, but spatial patterns of WMHs could underlie different risk factors and neuropathological and clinical correlates. We investigated the spatial heterogeneity of WMHs and their association with comorbidities, Alzheimer’s disease (AD) risk factors, and cognition. In this cross-sectional study, we studied 171 cognitively unimpaired (CU; median
-
A systematic review of progranulin concentrations in biofluids in over 7,000 people—assessing the pathogenicity of GRN mutations and other influencing factors Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-28 Imogen J. Swift, Rosa Rademakers, NiCole Finch, Matt Baker, Roberta Ghidoni, Luisa Benussi, Giuliano Binetti, Giacomina Rossi, Matthis Synofzik, Carlo Wilke, David Mengel, Caroline Graff, Leonel T. Takada, Raquel Sánchez-Valle, Anna Antonell, Daniela Galimberti, Chiara Fenoglio, Maria Serpente, Marina Arcaro, Stefanie Schreiber, Stefan Vielhaber, Philipp Arndt, Isabel Santana, Maria Rosario Almeida
Pathogenic heterozygous mutations in the progranulin gene (GRN) are a key cause of frontotemporal dementia (FTD), leading to significantly reduced biofluid concentrations of the progranulin protein (PGRN). This has led to a number of ongoing therapeutic trials aiming to treat this form of FTD by increasing PGRN levels in mutation carriers. However, we currently lack a complete understanding of factors
-
ANU-ADRI scores, tau pathology, and cognition in non-demented adults: the CABLE study Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-26 Shan Yin, Pei-Yang Gao, Ya-Nan Ou, Yan Fu, Ying Liu, Zuo-Teng Wang, Bao-Lin Han, Lan Tan
It has been reported that the risk of Alzheimer’s disease (AD) could be predicted by the Australian National University Alzheimer Disease Risk Index (ANU-ADRI) scores. However, among non-demented Chinese adults, the correlations of ANU-ADRI scores with cerebrospinal fluid (CSF) core biomarkers and cognition remain unclear. Individuals from the Chinese Alzheimer’s Biomarker and LifestyLE (CABLE) study
-
Potential ocular indicators to distinguish posterior cortical atrophy and typical Alzheimer’s disease: a cross-section study using optical coherence tomography angiography Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-25 Yan Sun, Lumi Zhang, Hui Ye, Lumin Leng, Yi Chen, Yujie Su, Peifang Ren, Hong Lu, Guoping Peng
Posterior cortical atrophy (PCA) is a form of dementia that frequently displays significant visual dysfunction and relatively preserved cognitive and executive functions, thus hindering early diagnosis and treatment. This study aimed to investigate possible fundus markers in PCA patients and compare them with those of typical Alzheimer’s disease (AD) patients to seek potential diagnostic patterns.
-
Navigating the metabolic maze: anomalies in fatty acid and cholesterol processes in Alzheimer’s astrocytes Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-23 Xiaoyu Zhang, Chuanying Chen, Yi Liu
Alzheimer’s disease (AD) is the most common cause of dementia, and its underlying mechanisms have been a subject of great interest. The mainstream theory of AD pathology suggests that the disease is primarily associated with tau protein and amyloid-beta (Aβ). However, an increasing body of research has revealed that abnormalities in lipid metabolism may be an important event throughout the pathophysiology
-
Impaired long-range excitatory time scale predicts abnormal neural oscillations and cognitive deficits in Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-19 Parul Verma, Kamalini Ranasinghe, Janani Prasad, Chang Cai, Xihe Xie, Hannah Lerner, Danielle Mizuiri, Bruce Miller, Katherine Rankin, Keith Vossel, Steven W. Cheung, Srikantan S. Nagarajan, Ashish Raj
Alzheimer’s disease (AD) is the most common form of dementia, progressively impairing cognitive abilities. While neuroimaging studies have revealed functional abnormalities in AD, how these relate to aberrant neuronal circuit mechanisms remains unclear. Using magnetoencephalography imaging we documented abnormal local neural synchrony patterns in patients with AD. To identify global abnormal biophysical
-
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-19 Ida Arvidsson, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Shorena Janelidze, Pontus Tideman, Anders Heyden, Karl Åström, Oskar Hansson, Niklas Mattsson-Carlgren
Predicting future Alzheimer’s disease (AD)-related cognitive decline among individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) is an important task for healthcare. Structural brain imaging as measured by magnetic resonance imaging (MRI) could potentially contribute when making such predictions. It is unclear if the predictive performance of MRI can be improved using
-
A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-14 Ying Zhang, Le Xue, Shuoyan Zhang, Jiacheng Yang, Qi Zhang, Min Wang, Luyao Wang, Mingkai Zhang, Jiehui Jiang, Yunxia Li
Functional connectivity (FC) biomarkers play a crucial role in the early diagnosis and mechanistic study of Alzheimer’s disease (AD). However, the identification of effective FC biomarkers remains challenging. In this study, we introduce a novel approach, the spatiotemporal graph convolutional network (ST-GCN) combined with the gradient-based class activation mapping (Grad-CAM) model (STGC-GCAM), to
-
Differences in the treatment needs of patients with dementia with Lewy bodies and their caregivers and differences in their physicians’ awareness of those treatment needs according to the clinical department visited by the patients: a subanalysis of an observational survey study Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-14 Manabu Ikeda, Shunji Toya, Yuta Manabe, Hajime Yamakage, Mamoru Hashimoto
We investigated whether the treatment needs of patients with dementia with Lewy bodies (DLB) and their caregivers, along with their attending physicians’ perception of those treatment needs, differ according to the clinical department visited by the patients. This was a subanalysis of a multicenter, cross-sectional, observational survey study. Data from the main study were classified according to the
-
Sex matters in the association between cardiovascular health and incident dementia: evidence from real world data Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-14 Anna Ponjoan, Jordi Blanch, Ester Fages-Masmiquel, Ruth Martí-Lluch, Lia Alves-Cabratosa, María del Mar Garcia-Gil, Gina Domínguez-Armengol, Francesc Ribas-Aulinas, Lluís Zacarías-Pons, Rafel Ramos
Cardiovascular health has been associated with dementia onset, but little is known about the variation of such association by sex and age considering dementia subtypes. We assessed the role of sex and age in the association between cardiovascular risk and the onset of all-cause dementia, Alzheimer’s disease, and vascular dementia in people aged 50–74 years. This is a retrospective cohort study covering
-
The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-12 Eunhae Shin, Sang Ah Chi, Tae-Young Chung, Hee Jin Kim, Kyunga Kim, Dong Hui Lim
In this study, the risk of dementia in patients with a history of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection was evaluated. This nationwide cohort study used data from the Korean National Health Insurance Service collected between 2006 and 2017. A total of 752,205 subjects ≥ 45 years of age not diagnosed with dementia until 2006 were included. A multivariate Cox regression
-
Amyloid β oligomer induces cerebral vasculopathy via pericyte-mediated endothelial dysfunction Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-12 Siqi Chen, Daji Guo, Yuanyuan Zhu, Songhua Xiao, Jiatian Xie, Zhan Zhang, Yu Hu, Jialin Huang, Xueying Ma, Zhiyuan Ning, Lin Cao, Jinping Cheng, Yamei Tang
Although abnormal accumulation of amyloid beta (Aβ) protein is thought to be the main cause of Alzheimer’s disease (AD), emerging evidence suggests a pivotal vascular contribution to AD. Aberrant amyloid β induces neurovascular dysfunction, leading to changes in the morphology and function of the microvasculature. However, little is known about the underlying mechanisms between Aβ deposition and vascular
-
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-11 Sheng-Min Wang, Dong Woo Kang, Yoo Hyun Um, Sunghwan Kim, Chang Uk Lee, Philip Scheltens, Hyun Kook Lim
Multimer detection system-oligomeric amyloid-β (MDS-OAβ) is a measure of plasma OAβ, which is associated with Alzheimer’s disease (AD) pathology. However, the relationship between MDS-OAβ and disease severity of AD is not clear. We aimed to investigate MDS-OAβ levels in different stages of AD and analyze the association between MDS-OAβ and cerebral Aβ deposition, cognitive function, and cortical thickness
-
Prediction of conversion from mild cognitive impairment to Alzheimer’s disease and simultaneous feature selection and grouping using Medicaid claim data Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-09 Qi Zhang, Ron Coury, Wenlong Tang
Due to the heterogeneity among patients with Mild Cognitive Impairment (MCI), it is critical to predict their risk of converting to Alzheimer’s disease (AD) early using routinely collected real-world data such as the electronic health record data or administrative claim data. The study used MarketScan Multi-State Medicaid data to construct a cohort of MCI patients. Logistic regression with tree-guided
-
Deciphering the effect of phytosterols on Alzheimer’s disease and Parkinson’s disease: the mediating role of lipid profiles Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-09 Xingzhi Guo, Jing Yu, Rui Wang, Ning Peng, Rui Li
Studies have suggested that blood circulating phytosterols, plant-derived sterols analogous to cholesterol, were associated with blood lipid levels and the risk of Alzheimer’s disease (AD) and Parkinson’s disease (PD). This Mendelian randomization (MR) study is performed to determine the causal effect of circulating phytosterols on AD and PD and evaluate the mediation effect of blood lipids. Leveraging
-
Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-08 Xinxin Huang, Shanshan Huang, Fangyan Fu, Junzhen Song, Yuling Zhang, Feng Yue
The key to the prevention and treatment of Alzheimer’s disease (AD) is to be able to predict and diagnose AD at the preclinical or early stage, but the lack of a preclinical model of AD is the critical factor that causes this problem to remain unresolved. We assessed 18 monkeys in vivo evaluation of pro-inflammatory cytokines and AD pathological biomarkers (n = 9 / type 2 diabetic mellitus (T2DM) group
-
Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer’s disease pathology Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-07 Anuschka Silva-Spínola, Maria João Leitão, Alicia Nadal, Nathalie Le Bastard, Isabel Santana, Inês Baldeiras
LUMIPULSE G-automated immunoassays represent a widely used method for the quantification of Alzheimer’s disease (AD) biomarkers in the cerebrospinal fluid (CSF). Less invasive blood-based markers confer a promising tool for AD diagnosis at prodromal stages (mild cognitive impairment (MCI)). Highly sensitive assays for the quantification of amyloid-beta (Aβ) and phosphorylated Tau-181 (p-Tau181) in
-
Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-07 Woo-Jin Cha, Dahyun Yi, Hyejin Ahn, Min Soo Byun, Yoon Young Chang, Jung-Min Choi, Kyungtae Kim, Hyeji Choi, Gijung Jung, Koung Mi Kang, Chul-Ho Sohn, Yun-Sang Lee, Yu Kyeong Kim, Dong Young Lee
Growing evidence suggests that not only cerebrovascular disease but also Alzheimer’s disease (AD) pathological process itself cause cerebral white matter degeneration, resulting in white matter hyperintensities (WMHs). Some preclinical evidence also indicates that white matter degeneration may precede or affect the development of AD pathology. This study aimed to clarify the direction of influence
-
Heterogeneity and overlap in the continuum of linguistic profile of logopenic and semantic variants of primary progressive aphasia: a Profile Analysis based on Multidimensional Scaling study Alz. Res. Therapy (IF 8.823) Pub Date : 2024-03-07 Gaia Chiara Santi, Francesca Conca, Valentina Esposito, Cristina Polito, Silvia Paola Caminiti, Cecilia Boccalini, Carmen Morinelli, Valentina Berti, Salvatore Mazzeo, Valentina Bessi, Alessandra Marcone, Sandro Iannaccone, Se-Kang Kim, Sandro Sorbi, Daniela Perani, Stefano F. Cappa, Eleonora Catricalà
Primary progressive aphasia (PPA) diagnostic criteria underestimate the complex presentation of semantic (sv) and logopenic (lv) variants, in which symptoms partially overlap, and mixed clinical presentation (mixed-PPA) and heterogenous profile (lvPPA +) are frequent. Conceptualization of similarities and differences of these clinical conditions is still scarce. Lexical, semantic, phonological, and
-
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-29 Linus Jönsson, Milana Ivkovic, Alireza Atri, Ron Handels, Anders Gustavsson, Julie Hviid Hahn-Pedersen, Teresa León, Mathias Lilja, Jens Gundgaard, Lars Lau Raket
The clinical meaningfulness of the effects of recently approved disease-modifying treatments (DMT) in Alzheimer’s disease is under debate. Available evidence is limited to short-term effects on clinical rating scales which may be difficult to interpret and have limited intrinsic meaning to patients. The main value of DMTs accrues over the long term as they are expected to cause a delay or slowing of
-
Correction: Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-27 Rong Jiang, Xue-Fei Wu, Bin Wang, Rong-Xiao Guan, Lang-Man Lv, Ai-Ping Li, Lei Lei, Ye Ma, Na Li, Qi-Fa Li, Quan-Hong Ma, Jie Zhao, Shao Li
Correction: Alz Res Therapy 12, 47 (2020) https://doi.org/10.1186/s13195-020-00616-3 Following publication of the original article [1], the authors identified an error in Fig. 6C (a). The corrected Fig. 6C(a) with the correct band and original data is given hereafter. The incorrect Fig. 6: Fig. 6 NgR reduction promotes APP trafficking to lysosomes by Rho/ROCK2 pathway. A (a, b) Representative bands
-
Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-27 Elaheh Moradi, Mithilesh Prakash, Anette Hall, Alina Solomon, Bryan Strange, Jussi Tohka
The pathophysiology of Alzheimer’s disease (AD) involves $$\beta$$ -amyloid (A $$\beta$$ ) accumulation. Early identification of individuals with abnormal $$\beta$$ -amyloid levels is crucial, but A $$\beta$$ quantification with positron emission tomography (PET) and cerebrospinal fluid (CSF) is invasive and expensive. We propose a machine learning framework using standard non-invasive (MRI, demographics
-
Polygenic effects on the risk of Alzheimer’s disease in the Japanese population Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-27 Masataka Kikuchi, Akinori Miyashita, Norikazu Hara, Kensaku Kasuga, Yuko Saito, Shigeo Murayama, Akiyoshi Kakita, Hiroyasu Akatsu, Kouichi Ozaki, Shumpei Niida, Ryozo Kuwano, Takeshi Iwatsubo, Akihiro Nakaya, Takeshi Ikeuchi
Polygenic effects have been proposed to account for some disease phenotypes; these effects are calculated as a polygenic risk score (PRS). This score is correlated with Alzheimer’s disease (AD)-related phenotypes, such as biomarker abnormalities and brain atrophy, and is associated with conversion from mild cognitive impairment (MCI) to AD. However, the AD PRS has been examined mainly in Europeans
-
GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-27 Mikel Tainta, Mirian Ecay-Torres, Maria de Arriba, Myriam Barandiaran, Ane Otaegui-Arrazola, Ane Iriondo, Maite Garcia-Sebastian, Ainara Estanga, Jon Saldias, Montserrat Clerigue, Alazne Gabilondo, Naia Ros, Justo Mugica, Aitziber Barandiaran, Francesca Mangialasche, Miia Kivipelto, Arantzazu Arrospide, Javier Mar, Pablo Martinez-Lage
GOIZ ZAINDU (“caring early” in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evaluate the feasibility and adherence to a FINGER-like multidomain intervention program. Additional aims included the assessment of efficacy on cognition and data collection to design a large efficacy
-
The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer’s disease continuum participants Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-20 Hui Hong, Luwei Hong, Xiao Luo, Qingze Zeng, Kaicheng Li, Shuyue Wang, Yeerfan Jiaerken, Ruiting Zhang, Xinfeng Yu, Yao Zhang, Cui Lei, Zhirong Liu, Yanxing Chen, Peiyu Huang, Minming Zhang
Glymphatic dysfunction is a crucial pathway for dementia. Alzheimer’s disease (AD) pathologies co-existing with cerebral small vessel disease (CSVD) is the most common pathogenesis for dementia. We hypothesize that AD pathologies and CSVD could be associated with glymphatic dysfunction, contributing to cognitive impairment. Participants completed with amyloid PET, diffusion tensor imaging (DTI), and
-
Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-20 Ainhoa García-Sánchez, Oscar Sotolongo-Grau, Juan Pablo Tartari, Ángela Sanabria, Ester Esteban - De Antonio, Alba Pérez-Cordón, Montserrat Alegret, Vanesa Pytel, Joan Martínez, Núria Aguilera, Itziar de Rojas, Amanda Cano, Pablo García-González, Raquel Puerta, Clàudia Olivé, Maria Capdevila, Fernando García-Gutiérrez, Assumpta Vivas, Marta Gómez-Chiari, Juan Giménez, Miguel Ángel Tejero, Miguel Castilla-Martí
Optical coherence tomography angiography (OCT-A) is a novel tool that allows the detection of retinal vascular changes. We investigated the association of macular vessel density (VD) in the superficial plexus assessed by OCT-A with measures of cerebrovascular pathology and atrophy quantified by brain magnetic resonance imaging (MRI) in non-demented individuals. Clinical, demographical, OCT-A, and brain
-
Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-19 Che Qiu, Wei Zhou, Hui Shen, Jintao Wang, Ran Tang, Tao Wang, Xinyi Xie, Bo Hong, Rujing Ren, Gang Wang, Zhongchen Song
The relationship between periodontitis and Alzheimer’s disease (AD) has attracted more attention recently, whereas profiles of subgingival microbiomes and gingival crevicular fluid (GCF) metabolic signatures in AD patients have rarely been characterized; thus, little evidence exists to support the oral-brain axis hypothesis. Therefore, our study aimed to characterize both the microbial community of
-
The role of perfusion, grey matter volume and behavioural phenotypes in the data-driven classification of cognitive syndromes Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-17 Ashwati Vipin, Bernett Teck Kwong Lee, Dilip Kumar, See Ann Soo, Yi Jin Leow, Smriti Ghildiyal, Faith Phemie Hui En Lee, Saima Hilal, Nagaendran Kandiah
The use of structural and perfusion brain imaging in combination with behavioural information in the prediction of cognitive syndromes using a data-driven approach remains to be explored. Here, we thus examined the contribution of brain structural and perfusion imaging and behavioural features to the existing classification of cognitive syndromes using a data-driven approach. Study participants belonged
-
Correction: Short leukocyte telomeres predict 25-year Alzheimer’s disease incidence in non-APOE ε4-carriers Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-16 Fernanda Schäfer Hackenhaar, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman, Sara Pudas
Correction: Alz Res Therapy 13, 130 (2021) https://doi.org/10.1186/s13195-021-00871-y Following the publication of the original article [1], the authors discovered that in contrast to what is stated in the article, the variable residualized leukocyte telomere length (rLTL) was not residualized for age, only gender. However, as the article describes, the effect of age and quadratic age were still accounted
-
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-16 María Eugenia Sáez, Ainhoa García-Sánchez, Itziar de Rojas, Emilio Alarcón-Martín, Joan Martínez, Amanda Cano, Pablo García-González, Raquel Puerta, Clàudia Olivé, Maria Capdevila, Fernando García-Gutiérrez, Miguel Castilla-Martí, Luis Castilla-Martí, Ana Espinosa, Montserrat Alegret, Mario Ricciardi, Vanesa Pytel, Sergi Valero, Lluís Tárraga, Mercè Boada, Agustín Ruiz, Marta Marquié
Several studies have reported a relationship between retinal thickness and dementia. Therefore, optical coherence tomography (OCT) has been proposed as an early diagnosis method for Alzheimer’s disease (AD). In this study, we performed a genome-wide association study (GWAS) aimed at identifying genes associated with retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GCIPL) thickness
-
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-16 Rawan Tarawneh, Vernon S. Pankratz
CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent, lecanemab, in mild cognitive impairment and mild dementia due to Alzheimer disease (AD). Lecanemab effectively reduced mean brain amyloid burden and was associated with statistically significant favorable effects, reflected by moderately less decline in the
-
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-15 Pierre N. Tariot, Mercè Boada, Krista L. Lanctôt, Julie Hahn-Pedersen, Firas Dabbous, Sariya Udayachalerm, Lars Lau Raket, Yuliya Halchenko, Wojciech Michalak, Wendy Weidner, Jeffrey Cummings
Understanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments. We examined associations among changes in Alzheimer’s disease (AD) stages and outcomes that are important to patients and their care partners including activities of daily living (ADLs), geriatric
-
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-14 Joseph R. Winer, Renske Lok, Lara Weed, Zihuai He, Kathleen L. Poston, Elizabeth C. Mormino, Jamie M. Zeitzer
Sleep-wake regulating circuits are affected during prodromal stages in the pathological progression of both Alzheimer’s disease (AD) and Parkinson’s disease (PD), and this disturbance can be measured passively using wearable devices. Our objective was to determine whether accelerometer-based measures of 24-h activity are associated with subsequent development of AD, PD, and cognitive decline. This
-
The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-14 Shreyasee Das, Marie-Paule E. van Engelen, Julie Goossens, Dirk Jacobs, Bram Bongers, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Charlotte E. Teunissen, Eugeen Vanmechelen, Inge M. W. Verberk
Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synaptic dysfunction is an early feature in bvFTD and identification of specific biomarkers might improve its diagnostic accuracy. Our goal was to understand the differential diagnostic potential of
-
Correction: Is later‑life depression a risk factor for Alzheimer’s disease or a prodromal symptom: a study using post‑mortem human brain tissue? Alz. Res. Therapy (IF 8.823) Pub Date : 2024-02-13 Lindsey I. Sinclair, Asher Mohr, Mizuki Morisaki, Martin Edmondson, Selina Chan, A. Bone‑Connaughton, Gustavo Turecki, Seth Love
Correction: Alz Res Therapy 15, 153 (2023) https://doi.org/10.1186/s13195-023-01299-2 Following the publication of the original article [1], the authors added the funder grant number (204813/Z/16/Z) of the Elizabeth-Blackwell institute for Health Research University of Bristol and the Wellcome Trust Institutional Strategic Support in Competing interests section. The original article [1] has been updated